Published on
September 8, 2023
- 08:00 GMT
Adrenomed presents new findings on its precision medicine treatment for septic shock with enibarcimab during Weimar Sepsis Update
Patient population benefitting most from enibarcimab treatment in septic shock can clearly be defined by two biomarkers, as shown by data presented today In the AdrenOSS-2 trial, the respective patient subgroup had a statistically significant >60% …
Distribution channels:
